rs778090540
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_031885.5(BBS2):c.1438C>T(p.Arg480Ter) variant causes a stop gained change. The variant allele was found at a frequency of 0.0000242 in 1,614,004 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.0000066 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000026 ( 0 hom. )
Consequence
BBS2
NM_031885.5 stop_gained
NM_031885.5 stop_gained
Scores
4
2
1
Clinical Significance
Conservation
PhyloP100: 4.92
Genes affected
BBS2 (HGNC:967): (Bardet-Biedl syndrome 2) This gene is a member of the Bardet-Biedl syndrome (BBS) gene family. Bardet-Biedl syndrome is an autosomal recessive disorder characterized by severe pigmentary retinopathy, obesity, polydactyly, renal malformation and cognitive disability. The proteins encoded by BBS gene family members are structurally diverse and the similar phenotypes exhibited by mutations in BBS gene family members is likely due to their shared roles in cilia formation and function. Many BBS proteins localize to the basal bodies, ciliary axonemes, and pericentriolar regions of cells. BBS proteins may also be involved in intracellular trafficking via microtubule-related transport. The protein encoded by this gene forms a multiprotein BBSome complex with seven other BBS proteins.[provided by RefSeq, Oct 2014]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 16-56499867-G-A is Pathogenic according to our data. Variant chr16-56499867-G-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 553353.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr16-56499867-G-A is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BBS2 | NM_031885.5 | c.1438C>T | p.Arg480Ter | stop_gained | 12/17 | ENST00000245157.11 | NP_114091.4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BBS2 | ENST00000245157.11 | c.1438C>T | p.Arg480Ter | stop_gained | 12/17 | 1 | NM_031885.5 | ENSP00000245157 | P1 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152164Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
1
AN:
152164
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000239 AC: 6AN: 251458Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135902
GnomAD3 exomes
AF:
AC:
6
AN:
251458
Hom.:
AF XY:
AC XY:
3
AN XY:
135902
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000260 AC: 38AN: 1461840Hom.: 0 Cov.: 30 AF XY: 0.0000289 AC XY: 21AN XY: 727226
GnomAD4 exome
AF:
AC:
38
AN:
1461840
Hom.:
Cov.:
30
AF XY:
AC XY:
21
AN XY:
727226
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152164Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74332
GnomAD4 genome
AF:
AC:
1
AN:
152164
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
74332
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
2
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Bardet-Biedl syndrome 2 Pathogenic:5
Likely pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 09, 2019 | The BBS2 c.1438C>T (p.Arg480Ter) variant is a stop gained variant which has been reported in at least five studies in which it is found in a total of four probands with Bardet-Biedl syndrome, including one in a homozygous state and three in a compound heterozygous state (Ansley et al. 2003; Janssen et al. 2011; Xing et al. 2014; Hirano et al. 2015; Olson et al. 2019). The homozygous individual and their unaffected father also carried two variants in cis in the BBS9 gene (Xing et al. 2014). In all families, the variant was identified in at least one unaffected parent in a heterozygous state. The variant was absent from 396 controls but is reported at a frequency of 0.00012 in the East Asian population of the Exome Aggregation Consortium. However, the frequency data are based on one allele, so the variant is presumed to be rare. Due to the potential impact of stop-gained variants and the supporting evidence, the p.Arg480Ter variant is classified as likely pathogenic for Bardet-Biedl syndrome. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Nov 18, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego | Oct 23, 2019 | This nonsense variant found in exon 12 of 17 is predicted to result in loss of normal protein function. This variant has been previously reported as a compound heterozygous or homozygous change in patients with Bardet-Biedl Syndrome, including thoraco-abdominal abnormalities and congenital heart defects (PMID: 21052717, 24608809, 26325687, 30293640). It is present in the heterozygous state in the gnomAD population database at a frequency of 0.0024% (6/251,458) and thus is presumed to be rare. Based on the available evidence, the c.1438C>T (p.Arg480Ter) variant is classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Aug 24, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 01, 2024 | - - |
Bardet-Biedl syndrome Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 19, 2019 | Variant summary: BBS2 c.1438C>T (p.Arg480X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 2.4e-05 in 251458 control chromosomes (gnomAD). c.1438C>T has been reported in the literature in individuals affected with Bardet-Biedl Syndrome (Hirano_2015, Janssen_2011, Xing_2014). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three ClinVar submissions (evaluation after 2014) cite the variant twice as pathogenic and once as likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 13, 2023 | This sequence change creates a premature translational stop signal (p.Arg480*) in the BBS2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BBS2 are known to be pathogenic (PMID: 11285252, 20177705, 24608809, 26518167). This variant is present in population databases (rs778090540, gnomAD 0.006%). This premature translational stop signal has been observed in individuals with Bardet-Biedl syndrome (PMID: 21052717, 24608809). ClinVar contains an entry for this variant (Variation ID: 553353). For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Feb 28, 2024 | Identified in the homozygous state or with a second pathogenic variant in multiple unrelated patients with features of Bardet-Biedl syndrome tested at GeneDx and in the literature (PMID: 21052717, 24608809, 26325687); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 25525159, 24608809, 30293640, 31877759, 35140360, 31964843, 33996183, ZhangQ2023[Preprint], 38034494, 36550847, 21052717, 26325687) - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
MutationTaster
Benign
A;A
Vest4
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at